430 related articles for article (PubMed ID: 9436028)
21. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
[TBL] [Abstract][Full Text] [Related]
22. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
23. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
25. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
26. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
[TBL] [Abstract][Full Text] [Related]
27. Establishment of two human prostate cancer cell lines derived from a single bone metastasis.
Navone NM; Olive M; Ozen M; Davis R; Troncoso P; Tu SM; Johnston D; Pollack A; Pathak S; von Eschenbach AC; Logothetis CJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2493-500. PubMed ID: 9815652
[TBL] [Abstract][Full Text] [Related]
28. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action.
Bigler D; Gulding KM; Dann R; Sheabar FZ; Conaway MR; Theodorescu D
Oncogene; 2003 Feb; 22(8):1261-72. PubMed ID: 12606954
[TBL] [Abstract][Full Text] [Related]
29. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
31. Development of human prostate cancer models for chemoprevention and experimental therapeutics studies.
Chung LW; Zhau HE; Wu TT
J Cell Biochem Suppl; 1997; 28-29():174-81. PubMed ID: 9589364
[TBL] [Abstract][Full Text] [Related]
32. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
34. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
Patel BJ; Pantuck AJ; Zisman A; Tsui KH; Paik SH; Caliliw R; Sheriff S; Wu L; deKernion JB; Tso CL; Belldegrun AS
J Urol; 2000 Oct; 164(4):1420-5. PubMed ID: 10992426
[TBL] [Abstract][Full Text] [Related]
35. Rap2 regulates androgen sensitivity in human prostate cancer cells.
Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
[TBL] [Abstract][Full Text] [Related]
36. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
[TBL] [Abstract][Full Text] [Related]
37. In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia.
Park HS; Cheon J; Cho HY; Ko YH; Bae JH; Moon DG; Kim JJ
Gene Ther; 2003 Jul; 10(13):1129-34. PubMed ID: 12808443
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
39. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
40. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.
Pettaway CA; Pathak S; Greene G; Ramirez E; Wilson MR; Killion JJ; Fidler IJ
Clin Cancer Res; 1996 Sep; 2(9):1627-36. PubMed ID: 9816342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
